Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma. Issue 9 (29th July 2021)

• Record Type: Journal Article
• Authors: Ollikainen, Riina K.; Kotkaranta, Pyry H.; Kemppainen, Janette; Teppo, Hanna-Riikka; Kuitunen, Hanne; Pirinen, Risto; Turpeenniemi-Hujanen, Taina; Kuittinen, Outi; Kuusisto, Milla E.L.
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 9(2021)
• Page Start: 2151
• Page End: 2160
• Publication Date: 2021-07-29
• Subjects: Chemokine -- diffuse large B-cell lymphoma -- testicular lymphoma -- systemic lymphoma; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2021.1913150
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Although treatment for diffuse large B-cell lymphoma (DLBCL) has taken some notable steps in the 2000s, there are still subgroups of patients suffering from high mortality and relapse rates. To further improve treatment outcomes, it is essential to discover new mechanisms of chemotherapy resistance and create new treatment approaches to overcome them. In the present study, we analyzed the expression of chemokines and their ligands in systemic and testicular DLBCL. From our biopsy sample set of 21 testicular and 28 systemic lymphomas, we were able to demonstrate chemokine profile differences and identify associations with clinical risk factors. High cytoplasmic CXCL13 expression had correlations with better treatment response, lower disease-related mortality, and limited stage. This study suggests that active CXCR5/CXCL13 signaling could overtake the CXCR4/CXCL12 axis, resulting in a better prognosis.